Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02159898 · ClinicalTrials.gov registry record · NA

EndoMAXX Endoluminal Valve Technology (EVT) Compared to EndoMAXX

A NA study of Malignant Esophageal Strictures, sponsored by Merit Medical Systems.

Completed
Registry status
NA
Development phase
60
Enrollment target
7
Study locations

NCT02159898 is a NA study of Malignant Esophageal Strictures that has completed, run by Merit Medical Systems. The registered enrollment target is 60 participants. The trial reports 7 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02159898, a NA study of Malignant Esophageal Strictures, has completed, sponsored by Merit Medical Systems.

COMPLETED
Registry status
NA
Development phase
60 participants
Enrollment target
7
Study locations

Study Summary

This is a prospective, single blinded, randomized study of EndoMAXX Endoluminal Valve Technology (EVT) Fully Covered Esophageal Stent with Valve for the treatment of malignant strictures of the lower esophagus. The purpose of this study is to evaluate improvement of dysphagia due to esophageal stricture with EndoMAXX Endoluminal Valve Technology (EVT) Fully Covered Esophageal Stent with Valve (investigational device) compared to the EndoMAXX Fully Covered Esophageal Stent (reference device).

Interventions

  • DEVICE EndoMAXX Endoluminal Valve Technology (EVT)
  • DEVICE EndoMAXX

Study Locations (7)

Colorado

  • University of Colorado Denver - Aurora

Florida

  • University of Florida - Gainesville

Indiana

  • Indiana University - Indianapolis

Minnesota

  • Mayo Clinic - Rochester

New York

  • Weill Cornell Medical College - New York

Pennsylvania

  • Geisinger Medical Center - Danville

Wisconsin

  • Medical College of Wisconsin - Milwaukee

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2015-01
Est. Completion 2016-12
Phase NA

Sponsor

Merit Medical Systems

18 total trials

What the Registry Record Tells You About NCT02159898

The ClinicalTrials.gov registry entry for NCT02159898 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merit Medical Systems, which has 18 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Malignant Esophageal Strictures appearing as the primary indexed condition, and to 2 interventions - of which EndoMAXX Endoluminal Valve Technology (EVT) is the first listed.

NCT02159898 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Colorado, Florida, Indiana.

Frequently Asked Questions

What is clinical trial NCT02159898 about?

NCT02159898 is a clinical study titled "EndoMAXX Endoluminal Valve Technology (EVT) Compared to EndoMAXX". This is a prospective, single blinded, randomized study of EndoMAXX Endoluminal Valve Technology (EVT) Fully Covered Esophageal Stent with Valve for the treatment of malignant strictures of the lower esophagus. The purpose of this study is to evaluate improvement of dysphagia due to esophageal stric...

What is the current status of trial NCT02159898?

This trial is currently completed. It is a NA study. The enrollment target is 60 participants. The study started on 2015-01. Estimated completion is 2016-12.

What conditions does trial NCT02159898 study?

This clinical trial studies the following conditions: Malignant Esophageal Strictures.

What interventions are being tested in trial NCT02159898?

The interventions under investigation include: EndoMAXX Endoluminal Valve Technology (EVT) (DEVICE), EndoMAXX (DEVICE).

Who is sponsoring clinical trial NCT02159898?

This trial is sponsored by Merit Medical Systems, which has 18 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02159898 being conducted?

This trial has 7 study locations across Colorado, Florida, Indiana, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.